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Summary 
Antibody VH transgenes containing small amounts of natural 5' and 3' flanking DNA undergo 
nonreciprocal homologous recombination with the endogenous Igh locus in B cells. The resulting 
"hybrid" heavy chain loci are generated at a low frequency but are fully functional, undergoing 
somatic hypermutation and isotype class switching. We have used this recombination pathway 
to introduce a somatically mutated variable (V) region with an unusually high affinity for the 
hapten p-azophenylarsonate (Ars) into the preimmune antibody repertoire.  The affinity of this 
V region for Ars is 100-fold higher than any unmutated anti-Ars antibody previously characterized. 
Expression of the transgene-encoded V region did not affect many aspects of antigen-driven B 
cell differentiation, including somatic hypermutation, in either Ars-specific  transgene- or endogenous 
V gene-expressing clones. Thus, the regulation of these processes appears to operate in a "global" 
fashion, in that the mechanisms involved are imperceptive of the relative affinities for antigen 
of the antibodies expressed by B cell clones participating in the immune response.  In contrast, 
the selection  of V region mutants leading to affinity  maturation and memory cell formation 
was found to be strongly influenced by the transgenic V region, but only in clones expressing 
this V region. Hybridomas derived from transgene- and endogenous V region-expressing memory 
cells were isolated at similar frequencies from individual transgenic mice. The V regions expressed 
by hybridomas in both of these groups had 2- to 30-fold greater affinity for Ars than their unmutated 
precursors,  despite the fact that the transgene-encoded precursors  had 100-fold higher affinity 
than their endogenous counterparts. These results show that the criterion for entry into the 
memory compartment is established not by the affinity of a B cell's V region relative to all other 
V regions expressed during the response, but by the affinity of this V region relative to its unmutated 
precursor. Thus, the development of B cell memory is regulated in a "clone-autonomous" fashion. 
T 
he nature of the B cell response to T cell-dependent an- 
tigens is extremely dynamic: extensive changes in both 
the clonal composition of the responding B cell population 
and the structure and function of the antibodies expressed 
by  this  population occur with  time  (1-3).  Isotype class 
switching alters the structure of antibody-constant regions, 
and somatic hypermutation of V region genes alters the struc- 
ture and function of antibody V domains. A stringent pro- 
cess of antigen selection, in concert with the hypermutation 
process, accounts for much of the phenomenon of antibody 
affinity  maturation (4-8). 
The hypermutation and affinity-based selection processes 
appear to take place largely in germinal centers (GC) 1 (9-11). 
t Abbreviations used in this paper: AFC, antibody-forming cell; Ars, p-azo- 
phenylarsonate; Bin, memory B cell; C, constant;  FDC, follicular dendritic 
cell; GC, germinal center; R, replacement;  S, silent. 
GCs form within the B cell follicles of secondary lymphoid 
organs after immunization and have long been recognized 
as sites of H chain class switching and memory B cell (Bm) 
development (12, 13). Models have been proposed suggesting 
that V gene hypermutation is induced and sustained in the 
rapidly proliferating population of GC B cells termed cen- 
troblasts (14-17).  These cells are then thought to exit the 
cell cycle and migrate to a region of the GC rich in follicular 
dendritic cells (FDC). FDC can retain antigen-antibody com- 
plexes on their surfaces for extended periods (18, 19). The 
B cells, now termed centrocytes,  are "tested" for the ability 
to bind with increased affinity to antigen present in these 
immune complexes.  Cells that "fail" the test die via apop- 
tosis; cells that "pass" either reenter the mutation-selection 
cycle or become memory cells. Most Bm cells express antigen 
receptors with increased affinity for antigen due to this mu- 
tation-selection process (20-24). 
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tigen and degree of B lymphocyte proliferation and differen- 
tiation is so fundamental to clonal selection-based models 
for the maturation of the B cell response  that this concept 
is often taken for granted. The importance of  a requisite affinity 
for the recruitment of clones at the onset of the response, 
as well as their ongoing participation in the mutation-selec- 
tion process, is well established  (for example,  see references 
25  and 26).  Yet,  the molecular mechanisms that translate 
affinity differences among B cells into proliferative  or sur- 
vival differences at these stages of differentiation remain vague. 
Moreover, whether relative afl~ty differences  directly influence 
clonal decisions  regarding (a) entry into antibody-forming 
cell (AFC) versus Bm pathways in the primary response,  (b) 
entry into and exit from GCs, (c) activity of the hypermuta- 
tion process,  and (d) establishment of the Bm cell compart- 
ment remain subjects  of speculation at present. 
We have described  a somatic nonreciprocal homologous 
recombination pathway leading to the incorporation of one 
copy of an antibody VH transgene, initially present in a va- 
riety of chromosomal locations and copy numbers, into the 
endogenous Igh locus in B cells (27, 28; Fig. 1). The resulting 
transgene-IgH "hybrid" loci encode fully functional H chains 
whose VH regions undergo somatic hypermutation and con- 
stant (C) regions undergo class switching upon immuniza- 
tion with an antigen for which the transgenic V~ confers 
specificity (29).  Allelic exclusion appears to be operative in 
B cells expressing  hybrid loci, as hybridomas derived from 
such cells express only one H chain isotype and, in some cases, 
lack  endogenous  VH  gene  segment  rearrangements  (28; 
Vora, K. A., and T. Manser,  unpublished results).  Due to 
the low frequency of these "transgene homologous targeting" 
events, only a small fraction of all B cells present in naive 
transgenic mice express  transgenic VH regions.  B  cells in 
which this recombination has not taken place do not express 
the transgene and, consequently, rearrange and express only 
endogenous VH gene segments. This recombination path- 
way provides for the subtle alteration of the antibody reper- 
toire by use of novel VH genes and gene constructs, thus al- 
lowing the fate of the B ceU clones that express these transgenes 
to be studied in the context of a naturally diverse immune 
repertoire. This approach differs fundamentally  from conven- 
tional Ig transgene approaches and embryonic stem cell-based 
Ig gene replacement strategies that result in major alterations 
of the antibody repertoire. 
Materials and Methods 
Transgenic Mice.  Transgenic mice were produced as described 
previously (27). Fertilized eggs from matings of C57BL/6xC3H 
F1 mice were injected with a linearized (at a unique NaeI site in 
vector sequences) pBluescript KS(-) (Stratagene  Inc., LaJolla, CA) 
plasmid construct containing the 36-71 VH gene and 150 bp and 
1.6 kbp of natural 5' and 3' flanking DNA, respectively  (Fig. 1). 
The plasmid lacked any "switch" or constant (C) region DNA. 
Immunization, Serology, and Generation of Hybridomas.  Mice  were 
given a primary i.p. injection of 100/zgp-azophenylarsonate  (Ars)- 
KLH in CFA. For serological  analyses, mice were bled on days 7, 
14, and 24, boosted on day 30 with 100 #g Ars-KLH in PBS, bled 
on day 40, and the levels of various antibodies were determined 
by ELISAs. Hybridomas were generated from spleen cells as de- 
scribed (30). Spleens were taken either 4, 7, or 12 d after primary 
immunization, 3 d after an i.p. injection of 100 #g Ars-KLH in 
PBS, administered I mo after primary immunization; or 3 d after 
three sequential  i.p. injections of 50/~g of  Ars-KLH in PBS, spaced 
at  3-d intervals, beginning  1 wk  after primary immunization 
(hyperimmunized). Total spleen cells were fused to Sp2/0.  Hy- 
bridoma supernatants were screened for mAbs reactive with Ars- 
BSA, and monoclonal anti-Id E4 by ELISA. Hybridomas in wells 
showing E4 reactivity were cloned by limiting dilution. The iso- 
types of the mAbs were determined  by ELISA  by use of  an isotyping 
kit (Hyclone Laboratories Inc., Logan, UT). 
DNA Isolation and Southern Blot Analysis.  DNA was isolated 
from hybridomas, tails, and spleens as described earlier (31). Se- 
quential Southern blotting analysis  was done as described (30) with 
an  XbaI-EcoRI  fragment  containing  the  IgH enhancer, then 
pBluescript KS(-). 
RT-PCR and Genomic DNA Amplifications.  Total  RNA was pre- 
pared from hybridomas as described by Chomczynski and Sacchi 
(32). 1-5/~g of total RNA was reverse transcribed by use of a 3' 
primer complimentary to a region in the Cul exon of the appro- 
priate C region gene. Subsequent PCR amplifications  were carried 
out with a 5' primer homologous to the leader exon of the Vuld  c~ 
gene segment. The light chain mRNA was reverse transcribed by 
use of a 3' C, primer and subsequently PCR amplified  by use of 
a 5' V~ primer specific for a region of the leader exon of the ca- 
nonical V~10 gene segment. 
DNA flanking the 3' side of VH genes in "hybrid" IgH loci was 
PCR amplified by use of hybridoma DNA and a nested primer 
approach. The 5' primer pair hybridized upstream of the CDR2 
region of the canonical  Vuld  cR gene segment. The 3' primer pair 
hybridized in the 3' intronic enhancer region of the endogenous 
Igk locus. 
Nucleotide Sequencing.  Nucleotide sequencing  was done by use 
of the  "fmol" PCR  sequencing kit  (Promega Biotech Corp., 
Madison, WI). PCR products were gel purified (Seaplaque; FMC 
Bioproducts, Rockland, ME) and sequenced by use of 32p end- 
labeled internal primers according  to the manufacturer's  instruction. 
Antibody Purification and Affinity Measurements.  mAbs were 
purified from hybridoma supernatants by affinity  chromatography 
on Ars-bovine gamma globulin Sepharose 4B as described previ- 
ously (33). Their affinities for Ars-tyrosine were determined by 
fluorescence quenching, also as described previously (34). 
PCR Analysis if'Hybrid" Loci and Estimation of  Precursor  Frequen- 
cies.  PCR detection of transgene Vu-Igk "hybrid" loci in trans- 
genic spleen DNA was accomplished by use of a nested primer 
approach, with primers described  previously  (29) that were specific 
for transgenic vector sequences and the enhancer region of the en- 
dogenous Igk locus, and the protocol ofLiu et al. (35). Target  copy 
number DNA standards were created by doing serial dilutions of 
DNA from a hybridoma containing a "hybrid" locus into DNA 
obtained from a mouse macrophage cell line. The  amount  of 
ethidium  bromide fluorescence  of the hybrid locus containing  2.2-kb 
bands obtained from the standard dilutions was compared with 
that obtained from identical amounts of transgenic spleen DNA, 
thus allowing estimation of the frequency  of spleen cells containing 
hybrid loci. This frequency  was estimated to be 1/104 to 1/105 for 
five of seven HAM29 transgenic mice. The fact that DNA from 
some transgenic mice did not give rise to a band predicted from 
a hybrid  locus indicates that in these mice such loci were not present 
in the spleen at the time of killing. 
The  VHId  cR  gene segment  is  expressed at  a  frequency of 
272  Global  and Clone-autonomous  Regulation of B Cell Differentiation 5'  """" -..~3J4 
.....  ~HI  I  I~~H  I  I 
NonhomologoE)~.r~esolut,o  n  ~  Homologous pairing 
.:'.".-..".".':-:...  I  I  I  I  ~  ........ ,  nnnn 
Nonreciprocall  recombination 
......  ~1~!1  I~fll  I 
.....  ~lml  I  ~  I  ,  nnnn 
3'  Germline transgenic 
array 
...... (Germline)  IgH 
locus 
......  -Transgenic  array 
....... "Hybrid"  locus 
Figure  1.  Schematic diagram of the recombi- 
nation pathway leading to the formation of trans- 
gene-lgH hybrid loci. Two sites of recombination 
are illustrated: the homologous recombination site 
(solid lines) and the nonhomologous recombination 
site (st@ed lines).  Regions of DNA are indicated 
by boxes filled in different patterns. The germline 
lgh locus is shown;  however, rearranged endoge- 
nous VDJ and DJ loci may also be substrates  of 
hybrid locus formation. B cells in transgenic mice 
express either a hybrid or a conventional H chain 
locus and also contain the original transgenic array 
due to the nonreciprocal  nature of this recombi- 
nation pathway.  W, pBluescript vector;  W, VDJ 
gene and leader intron/exon; @, IgH enhancer/ 
MAP,;  I,  unjoined J  segments  in JH  region; 
[~[~[-][-], constant region exons; ~, switch DNA. 
,~1/200 among B cell hybridomas  isolated from the polyclonally 
activated splenic  B cells of A/J mice. Sequencing  of the VH genes 
expressed by such hybridomas  reveals a rather random utilization 
of D and JH gene segments (36). Therefore,  we estimate that the 
frequency  of expression of canonical V, genes among naive  B cells 
in A/J mice is ~1/104 (1/200 V,s  x  1/15 Ds  x  1/4 JHs). The 
influence  of N region addition has been ignored  in this calculation, 
since canonical  V genes  contain few N region nucleotides  at both 
V,-D and D-JH  junctions, and many amino acid  combinations  en- 
coded at these  junctions are compatible  with specificity  for Ars (37). 
Results 
During  the anti-Ars  response in  A/J mice,  antibodies 
encoded  by  a  single  combination  of VH  (VHIdCR), D 
(DFL16.1), JH (JH2), V~ (V~IdCR-VA0),  and J~ (JA) gene 
segments become predominant (21). We term this combina- 
tion, and the antibodies it encodes, "canonical:'  The proto- 
type unmutated canonical mAb is expressed by hybridoma 
36-65. Canonical V regions undergo hypermutation and an- 
tigen af~nity-based selection during the anti-Ars response, 
resulting in an anti-Ars Bm compartment in which mutated 
canonical V regions with 5- to 20-fold increased affinity rela- 
tive to their unmutated counterparts predominate (8, 21). 
The somatically mutated canonical mAb produced by hy- 
bridoma 36-71 0 8) has a Ka for Ars-tyrosine of 3-5  x  107 
M-i (34, 39), the highest af~nity anti-Ars mAb from A/J 
mice yet characterized. The af~nity of 36-71 is at least 100- 
fold higher than mAbs encoded by the unmutated combina- 
tion of canonical V segments, such as 36-65 (K~ 2-4  x  105 
M-1). Three amino acid substitutions  in the VH region of 
36-65 reproduce much of this 100-fold higher af~nity: two 
substitutions  in CDR 2 (T58 -* I; K59 -~ T) and a third 
at the D-J  junction in CDR3 (Y100 ~  K). Mutations present 
in the 36-71 V~ do not play a major role in the af~nity in- 
crease, as the 36-71 H chain can combine with the 36-65 L 
chain, resulting in little change in affinity compared with 
36-71 (39). An x-ray crystal structure of 36-71 Fab is avail- 
able and has been refined to 1.85 ]l  (40). B cells expressing 
a V region encoded by both a hybrid H chain locus containing 
a 36-71 VH transgene and an endogenous canonical V, gene 
would bear a structurally characterized, somatically mutated, 
high af~nity antigen receptor representative of an ultimate 
product of the mutation-selection pathway leading to the 
differentiation  of Bm cells. 
Transgenic mice were generated by use of a plasmid con- 
struct containing the 36-71 VH gene and 150 bp and 1.6 kbp 
of natural 5' and 3' flanking DNA (derived from a genomic 
clone of the 36-65 VH gene), respectively, including the VH 
promoter and the JH3-JH4 region, but lacking the intronic 
enhancer and switch and C region DNA (Fig. 1). Founder 
lines were backcrossed at least twice to A/J mice to obtain 
the mice used here. Three lines were used in our studies con- 
taining 8-10 (HAM29),  5-6 (HAM61), and 2-3 (HAM57) 
copies of the transgene, although the HAM29 line was used 
most extensively. 
We could detect the transgene-IgH hybrid loci resulting 
from homologous recombination of the HAM29 transgenic 
array with the endogenous Igh locus by PCR analysis  of spleen 
DNA. Standards indicated that spleen cells containing such 
loci were present at a frequency of 1/104  to  1/105.  Tram- 
gene-encoded antibody could not be detected in preimmune 
sera of any of the lines of mice. Four fusions of lipopoly- 
saccharide  plus dextran sulfate-stimulated splenic B cells from 
HAM29 transgenic mice yielded "~5,000 hybridomas, none 
of which secreted transgene-encoded Ars-binding  antibody 
(data  not  shown).  These results  suggest  that  VH 36-71- 
transgenic mice have a very low frequency of cells in their 
"naive" B cell compartment that have generated and express 
transgene-IgH hybrid loci. A low precursor frequency has 
also been estimated for canonical VH regions encoded by en- 
dogenous V gene segments (36; see Materials and Methods 
for calculations). 
Models for Participation of 36-71 Vn Transgene-expressing B 
Cells in the Anti-An Response.  Models for the participation 
in an immune response to Ars of a B cell initially expressing 
a V region encoded by the 36-71 V. transgene and a canon- 
ical, unmutated V~ gene are shown schematically in Fig. 2. 
Since it expresses a "memory type" antigen receptor, this cell 
might be directly recruited into the Bm compartment, effec- 
tively bypassing the GC/mutation-sdection pathway (Fig. 
2 A). A cell expressing this receptor might e~ciently cap- 
ture soluble antigen, resulting in predominant induction and 
focusing of T cell help early in the response before GC for- 
mation. This might lead to extensive donal expansion fol- 
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pressing a 36-71-transgenic  VH gene and an endogenous  canonical V~ 
gene. GC, germinal centers; *, V region somatic mutations. "Naive" B 
cells are shown containing light gray nuclei. Memory B cells are shown 
containing  black nuclei. AFCs are illustrated as ellipsoid cells. (.4) Direct 
recruitment to memory, bypassing or only transiently passing through 
germinal centers. (B) Proliferation and direct differentiation into AFCs. 
(C) Exclusive and precocious entry into germinal centers. (D) Participa- 
tion in both GC/Bm and AFC pathways. 
lowed by rapid terminal differentiation to AFC phenotype 
(Fig. 2 B). B cell clones expressing this receptor might seed 
GCs quickly, leading to the precocious somatic mutation and 
affinity maturation of their V regions (Fig. 2 C). Finally, the 
effect of the high affinity "memory type" antigen receptor 
might be simply quantitative, allowing dominant participa- 
tion of B cells expressing  it in both the primary AFC and 
GC/Bm pathways  (Fig. 2 D). 
Expression of Serum Anti-An Antibodies in Vu 36-71 Tram- 
genic Mice.  12 HAM29 transgenic mice and 8 transgene- 
negative littermates were immunized  with Ars-KLH and bled 
7,  14, and 24 d later, and then boosted with Ars-KLH and 
bled 10 d later. Sera were analyzed for levels of anti-Ars  and 
anti-KLH antibodies and idiotopes recognized by the mAbs 
E4 and AD8. E4 recognizes all unmutated and mutated forms 
of canonical V regions that have been tested (30, 41, 42; Vora, 
K. A., and T. Manser, unpublished observations).  The com- 
bination of a 36-71 H  chain and an unmutated canonical L 
chain is E4 + but does not express detectable  levels of the 
AD8 idiotope (42).  All antibodies encoded by the VHId  cR 
gene segment in unmutated form are ADS + (36). 
Transgenic mice and their nontransgenic  littermates showed 
similar kinetics of expression of anti-Ars antibodies and the 
two idiotopes (Table 1). The anticarrier (KLH) response was 
indistinguishable in the two groups (data not shown). Sig- 
nificant levels of anti-Ars or idiotype-bearing antibodies were 
not detected on day 7 in either group. However,  levels of 
anti-Ars  and E4 +  antibodies in the transgenic mice were 
higher than in the littermates at days 14 and 24 of the pri- 
mary and in the secondary response. Over 50% of the binding 
of the anti-Ars antibodies present in pooled day-24 sera from 
the transgenic animals was inhibited by low concentrations 
of free Ars-tyrosine (10-100/~M),  indicating that a major 
subfraction of this antibody had high affinity for Ars. This 
high affinity subfraction was absent from pooled day-24 sera 
obtained from the nontransgenic littermates (data not shown). 
Since transgene-encoded antibodies are ADS-, expression 
of the ADS idiotope provides a direct measure of the endog- 
enous (particularly the primary) anti-Ars response. The level 
Table  1.  Serum Antibody Levels in  Vu 36-71-transgenk Mice and Nontransgenic Littermates 
Primary day 14  Primary day 24  Secondary day  10 
ARS  AD8  E4  ARS  AD8  E4  ARS  AD8  E4 
/,g/ml  /,g/ml  /~g/rnl 
TG +  Range  36-197  13-138  0-30  30-2,400  14-851  15-1,500  666-10,000  35-1,100  198-4,900 
Average  89  55  9  489  215  465  3,364  433  1,273 
TG-  Range  20-107  10-100  0-25  49-219  35-276  7-1,160  800-2,900  49-2,400  99-3,300 
Average  55  43  6  108  126  238  1,534  972  1,081 
12 HAM29 transgenic  (TG +) and 8 nontransgenic littermates  (TG-) were immunized with Ars-KLH and bled at various times as described in 
Materials and Methods.  Serum levels of Ars-BSA binding antibody (ARS) and AD8 and E4 idiotopes were determined by ELISA and are expressed 
as micrograms per milliliter equivalents of the mAb 36-65. The range and average of these levels obtained for each group of mice at each time point 
are  shown. 
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imately twofold at any time between transgenic  and non- 
transgenic animals, demonstrating that participation of B cells 
expressing  endogenous V~IdC~,-encoded  antibodies  in the 
AFC response was not greatly  altered due to the participa- 
tion of transgenic  VH-expressing clones.  Moreover,  these 
data suggest that the majority of the additional, high afiinity 
serum  anti-Ars  antibody in the transgenic  mice is derived 
from 36-71 V~-IgH  hybrid locus-expressing B cells. 
H~bridoma Analysis of the Participation of VH 36-71-ex- 
pressing B Cell Clones in the Primary and Secondary Anti-Ars 
Responses.  B call hybridomas were generated from HAM29 
transgenic mice at days 4, 7, and 12 during the primary anti- 
Ars response and were screened for the secretion of anti-Ars 
antibody and the E4 idiotope.  Use of E4 allowed equally 
ef~dent identification of wells containing canonical antibodies 
encoded by endogenous V~ segments or the transgenic VH. 
Of 12 fusions performed,  10 yielded Ars § hybridomas (2-10 
positive wells each), and of these, 5 yielded E4 + hybridomas. 
Among hybridomas obtained from the latter fusions, '~20% 
of the Ars + primary hybridomas  were also E4 +. Represen- 
tative E4 + hybridomas  were subcloned and their expressed 
VH  and V~  genes  were  sequenced.  All  seven  of the  VH 
regions  analyzed (one from day 4, two and three from day 
7, and one from day 12) are transgene encoded and are ex- 
pressed as either IgG3 (one hybridoma) or IgG1 (six hybrid- 
omas)  H  chains.  These V~ regions lack somatic mutations 
in addition to those encoded in the 36-71 transgene. Southern 
blot analysis of genomic DNA  isolated  from the E4 + hy- 
bridomas  confirmed the presence of transgene-IgH hybrid 
loci. All of these hybridomas also express unmutated, canon- 
ical V~ genes identical  to those expressed by conventional 
A/J mice (data not shown). These results contrast with those 
we obtained  from mice containing a 36-65  VH transgene 
capable of forming hybrid loci, in which both E4 + hybrid- 
omas expressing canonical endogenous or transgenic V genes 
were isolated  at day 7 of the primary  anti-Ars  response at 
a low  frequency.  In  these  experiments,  36-65  Vu  trans- 
gene-expressing hybridomas were isolated at a frequency of 
'~5% of all Ars + hybridomas (Manser, I"., unpublished ob- 
servations). 
To study the participation of transgene-expressing  B cells 
in the anti-Ars  Bm pathway,  10 36-71 Vs-transgenic mice 
(1  mouse  each  of the  HAM61  and HAM57  lines and 8 
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.......  C ..... ~  --~  ....  A ...............  G  GAG  ...........  AAG  ...... 
....................  A ...............  G  GAG  ................  AAG  ........ 
....................  A ......  T  -  --~  --G  GAG  ..............  ~  AAG  ..... 
................  A-  --~  ..........  G  GAG  .................  AAG  ..... 
......................  A .............. G  GAA  ...............  AA~  .......... 
...................  A ..........  G  GAG  .................  AAG  ...... 
.................  A .............  G  GAG  ..................  AAG  ..... 
.....................  A ..............  G  GAG  .......  AAG  ........ 
.....  G ......  A .........  ~  G  GAG  --~  .............  AAG  -  -- 
...........  ~  ....  A ........  G  GAG  ......  AAG 
.....  ~  ..........  ~  ....  A .............  G  GAG  --~  ..............  AA~  ..... 
....................  A ...........  G  GAG  ............  AAG  ........ 
....................  A ...........  G  GA~  ...............  AAG  .... 
......  A ............  A  ..............  G  GA~  ........  AAG  ........ 
...................  A ............  G  GAG  ..................  AAG  ........ 
....................  A  .............  G  GAG  .............  AAG  ......... 
-T ....  A ..............  A ...............  G  GA~  AAG  ......... 
.............  A  ..............  G  GAG  ..........  AAG  ..... 
...............  ~  -A-  --G  GAG  ....  AAG  .... 
Figure  3.  Nucleotide sequences 
of  the  36-71  VH  transgenes  ex- 
pressed by hybridomas isolated from 
secondary and hyperimmune anti- 
Ars  responses.  The sequences  are 
compared  with  the prototype  se- 
quence of unmutated canonical VH 
genes  (CANONICAL)  and  the 
36-71 VH transgene (3671).  Amino 
acid codons are numbered sequen- 
tially, beginning with the mature 
amino terminus. Sequence identity 
to the canonical  sequence  is indi- 
cated  by  a  dash; differences  are 
shown explidtly. Transhtionally si- 
lent mutations are underlined. Only 
the codons in which mutations were 
observed are shown, with the ex- 
ception  of codons  I  (the  mature 
amino terminus), 121, and those en- 
coding the D region.  The position 
of CDR  codons  (underlined)  and 
regions encoded by D and JH2 gene 
segments  are  also  indicated.  Se- 
quences  derived  from  individual 
mice  are  shown  in  groups.  The 
name of each hybridoma, as well as 
the isotype of the antibody it ex- 
presses, are listed at the beginning 
of each sequence. Sequences derived 
from mice from which endogenous, 
canonical  VH-expressing  hybrid- 
omas were also isohted are indicated 
by names in bold lettering. The two 
sequences obtained from the single 
hyperimmunized mouse are  sepa- 
rated by a solid line. The prototype 
sequence  data are  available from 
EMBL/GenBank/DDBJ under acces- 
sion numbers M20274 and M31909. 
275  Vora and Manser HAM29 mice) were immunized  with Ars-KLH,  rested for 
1 mo, and then boosted with Ars-KLH and spleen cells used 
for hybridoma formation. One HAM29 mouse was hyperim- 
munized with Ars-KLH (see Materials and Methods) before 
fusion.  Hybridoma  screening and VH and V~  sequencing 
were carried out as described above. Nine of the fusions gave 
rise to E4 + hybridomas, and roughly  equal proportions of 
these hybridomas were subsequently found to express trans- 
genic or endogenous VH regions. To rule out the possibility 
that some transgene-encoded antibodies were not being de- 
tected in the screens due to loss of the E4 idiotope,  the ex- 
pressed Vns  of representative Ars+E4 -  hybridomas from 
two of the  HAM29  fusions  that  yielded  E4 +  transgene- 
encoded mAbs were subjected to partial sequencing analysis. 
Of 17 such hybridomas, none were found to express transgene- 
encoded Vn genes. 
Representative transgene-expressing hybridomas chosen 
from all of the secondary fusions for detailed V gene sequencing 
express IgG3 (2 hybridomas), IgG2a (2 hybridomas), and IgG1 
(15 hybridomas) H chains (Fig. 3). The other E4 + hybrid- 
omas express canonical V regions entirely encoded by endog- 
enous V gene segments, in the form of IgG3 (2 hybridomas) 
and IgG1 (16 hybridomas) H chains (Fig. 4).  In six of the 
mice, both hybridomas expressing transgene or endogenous 
VH gene-encoded  V regions were isolated (e.g.,  the 3F29-4 
group). All the E4 + hybridomas express canonical V~ genes, 
identical except for somatic mutations to those expressed by 
conventional A/J mice (data not shown). Results from related 
studies on 36-65 Vn-transgenic mice showed that secondary 
anti-Ars E4 + hybridomas isolated from these mice express 
hybrid loci at a lower frequency (10-20%) than was found 
for  the  36-71  Vu-transgenic  mice  (Vora, K.  A.,  and  T. 
Manser, manuscript in preparation). 
Analysis of Somatic Mutations in 36-71 VH Transgenes and 
Endogenous VH Genes Expressed by  Secondary Hybridomas. 
Analysis of both 36-71 transgenic Vn--expressing and endog- 
enous  Vn-expressing  secondary E4 §  hybridomas revealed 
extensive somatic mutation  of their functional VH and V~ 
CDR1 
1  i0  Ii  12  15  20  22  24  27  29  31  32  34  42  46 
CANONICAL  TCT  GCT  GAG  CTG  GCT  AT(3  TGC  GCT  TAT  TTC  AGC  TAC  ATA  GGA  GAA 

















FF29-12  6 
eD~ 
49  50  51  52  55  56  58  59  63  64  66  67  69 
GGA  TAT  ATT  AAT  AAT  GGT  ACT  AAG  AAG  TTC  GGC  AAG  ACA 
--  T  ......................  A  T  ......  AC  .....  T  C  ......... 
G]  .........................  T  ...... 
G3  .............................................. 
G1  ....... C  ......  ~  -C  ............  G  --  -T~  c  C  -A  --G  ......... 
G1  .........  A .......  ~  -  -C .................  G  --  "T-  C-C  C  .......  C .... 
G1  C ....  A  ................  T~  ---  A .................  T  CC  --~  "--  CT 
G3  .......................  A ............  C  ......... 
GI  ......  A  ..............  ~  ......  A ......  TT  ..... 
G1  ......................  A  ............................. 
G1  ............................................... 
G1  ........  ~  ...........  T .....  T  ---  A  .... 
Gl  ................................  T ....  G  -T  .... 
G1  ........................  T  ......  ~  --  -  A  .....  G  ...... 
G1  .........................  C  .......... 
GI---  A  ..........  A  ---  -  T .....  T  .......  C  .....  A  -" 
G1  ....  A  ................  A ........  AT-  --  C  ......... 
G1  ..........................  C  .....  T  ....... 
G1  ..................................  T  -T  -  G ......... 
3F29-6-5  Ol  .............  T  ........  ~  A  ........  C  .........  T  GC  .......... 
71  73  74  77  78  80  81  82  83  86  89  93  94  95  97  99 
CANONICAL  ACT  GAC  AAA  AGC  ACA  TAC  ATG  CAG  CTC  CTG  GAG  GTC  TAT  TTC  GCA  TCN 
36  7]  .......  A ......................  G 
l  .............  G  --T  .... T 
14  .....................  C 
4  .................................  G 
12  ...................  G 
14  .............................  G 
43  ......  T  ---  A .....  A  ..........  A 
El  ...........  A .........  G 
E:  ......................  c 
E3  Z_-  2Z-z-  c 
E4  ........  C  ....  C 
E5  -  C  -  C 
E6  ...................  ~  T  C 
1  ........  G 
2  ￿9  T 
4  --  -  C  .....  G 
5  ~  G  ........  T  ~  G 
6  .................................................  G 
D  RBOION  ~ 
100  101  102  103  104  105  106  107  108  109  ii0  iii  121 
NNN  TAC  TAT  GGT  GGT  AGT  TAC  NNN  TTT  GAC  TAC  TGG  TCA 
GAG  ..................  AAG  ........... 
CAT  -  -  -  C  --  TAC  .... 
CAT  -  --C  --T  TCT  ATG  ......  JH4 
AAT  -  --T  TGC  .......... 
AAT  ............  TCC 
AAT  ..............  T  TGC  .......... 
GAT  ......  C  ---  ATA  .......... 
GAG  ...........  CC  --  TCC  ......... 
CAT  ........  C  --T  GCT  ATG  .........  JH4 
CAT  .....  C  --T  GCT  ATG  JH4 
CAT  .....  C  -T  TCT  ATG  .........  OH4 
CAT  C  .-T  AGT  ATG  ---  JH4 
'PAT  ...........  C  --T  GCT  ATG  ....  JN4 
GAT  ......  TAC  A  ...... 
CAT  C  "~  TCC  ....... 
GAT  ..................  TAC  .--  A  --- 
GAT  "  TTC  A  ...... 
GAA  ...............  T  TAC  C  ..... 
5  .......  ~  ""  A  ~  ....  G  CTT  -  C  -~  TAC  -  G  --- 
Figure  4.  Nudeotide  sequences  of the endogenous canonical  VH genes expressed  by hybridomas  isolated from the secondary  anti-Ars  response  of 
36-71 VH-transgenic mice. Sequences  are illustrated  as described  in the legend to Fig.  3. The names  of hybridomas  isolated  from  mice from which 
transgene  VH-expressing hybridomas  were also isolated are shown in bold lettering.  The  prototype sequence  data are available from  EMBL/Gen- 
Bank/DDBJ  under accession  numbers  M20274 and M31909. 
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data not shown).  However, the mutation frequency in the 
transgenic V. genes is twofold lower than in the endoge- 
nous canonical Vrt genes.  Moreover, the majority of muta- 
tions in the transgenic VH sequences are translationally si- 
lent (S) (Figs. 3 and 4, underlined mutations), while the major 
fraction of mutations in the endogenous VH genes encode 
amino acid replacements (R) (Fig.  4). The frequency, type, 
and distribution of mutations in these endogenous VH genes 
are similar to what have been observed previously in the ca- 
nonical V. genes expressed by secondary anti-Ars hybrid- 
omas isolated from conventional A/J mice (43). 
An analysis of the distribution and type of somatic muta- 
tions observed in the VH genes expressed by the secondary 
hybridomas isolated from the transgenic mice is summarized 
in Table 2. The frequency orS mutations should not be affected 
by antigen selection, so positive selection for K  mutations 
will result in a large R/S ratio, while negative selection of 
such mutations will result in a small R/S ratio (44). Muta- 
tions in the endogenous canonical VH genes have an overall 
R/S ratio that is more than three times greater than the mu- 
tations in the transgenes. Moreover, the K/S ratio of muta- 
tions in CDKs of endogenous VH genes is "~10-fold higher 
than in the CDRs of the transgenes.  However, the overall 
frequencies of S mutations in the two types of V. gene are 
comparable.  These data suggest that while the extent of muta- 
tional alteration of transgenic and endogenous VH genes was 
similar during the generation of the Bm compartment, most 
K  mutations in the transgenes were selected  against.  Con- 
currently, positive selection of K  mutations in CDKs took 
place  in endogenous VH genes. 
Table  2.  Analysis of Somatic Mutations in Canonical Vu Genes 
Expressed by Secondary Hybridomas 
Mutation 
V. gene  frequency  K/S ratio 
% 
Transgene encoded  0.79 (S  -  0.40)  0.89 
CDRs  1.17  1.20 
FWs  0.64  0.81 
J.2-J.3 3' flank  1.70 
Endogenous  1.48 (S  =  0.35)  3.1 
CDRs  2.39  10.25 
FWs  1.07  1.65 
The percent frequency  of mutation (total mutations/total  nucleotides  se- 
quenced x 100)  and the R/S ratio (number of mutations causing amino 
acid replacements/number  that do not) were calculated  for the transgen- 
ic and endogenous Vn genes whose sequences are presented in Figs. 3 
and 4, as well as for the CDK (1, 2, and 3) and FW subregions of these 
genes. The frequency  of silent (S - ) mutations in these VH genes is also 
shown, as is the frequency  of mutations in the 500 bp of DNA flanking 
the Y side of four of the transgenic VH genes (JH2-J.3 y  flank). 
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This conclusion is substantiated by the results of an anal- 
ysis of the mutation frequency in the 500 bp of  DNA flanking 
the 3' side  of transgenic VHs present in the hybrid loci of 
secondary hybridomas.  This region has been shown to be 
as "mutable" as VH coding sequence (29,  45) but does not 
encode protein that can be subjected to selective forces. The 
frequency of mutation in this region is 1.7%, approximately 
twice the frequency observed in the adjacent coding sequence 
but analogous to the 1.48% frequency of mutation observed 
in coding sequence of endogenous V, genes (Table 2).  In 
addition, the frequencies and R/S ratios of mutations in en- 
dogenous canonical V,  genes expressed by the transgenic 
and endogenous Vu-expressing hybridomas are very similar 
(0.77%  and 2.0;  1.0%  and  1.69,  respectively). 
Affinity  Measurements of Vu 36-71 Transgene-encoded and 
Endogenous Vu Gene-encoded Canonical Antibodies.  The in- 
trinsic affinities of mAb produced by representative secondary 
hybridomas isolated from the transgenic mice for Ars-tyrosine, 
which represents the major arsonate B cell epitope on Ars- 
KLH, were measured by fluorescence quenching. Monoclonal 
antibody FF29-34-1, expressed by a hybridoma isolated on 
day 4 of the primary response, whose V region is encoded 
by the unmutated 36-71  transgenic VH and an endogenous 
unmutated canonical V~ gene, was used to determine the 
"germline" affinity of B cell antigen receptors of this type. 
Table 3.  Affinities of VH 36-71 Transgene and Endogenous VH 
Gene-encoded Canonical Antibodies 
Monoclonal  Transgene 
antibody  Response  encoded?  Ka (M- ') 
FF29-34-1  Primary  +  2.9  x  107 
FF29-15-1  Secondary  -  4.8  x  l& 
FF29-15-4  Secondary  +  3.3  x  107 
FF29-36-14  Secondary  -  4.8  x  10  s 
FF29-36-2  Secondary  +  9.4  x  107 
FF29-36-9  Secondary  +  4.0  x  107 
FF29-36-15  Secondary  +  6.7  x  107 
3F29-4-4  Secondary  -  1.1  x  106 
3F29-4-12  Secondary  -  4.6  x  l& 
3F29-4-14  Secondary  -  1.1  x  107 
3F29-4-5  Secondary  +  8.8  x  107 
3F29-4-15  Secondary  +  5.6  x  107 
3F29-5-43  Secondary  -  9.4  x  l& 
The affinity of each purified mAb for Ars-tyrosine was determined by 
fluoresence  quenching and is shown as a molar association constant (K,). 
The anti-Ars response  from  which the hybridoma  producing  each mAb 
was isolated is indicated (Response) as is whether the mAb is encoded 
by the 36-71 transgene  (Transgene  encoded?),  mAbs derived  from individual 
mice and the data pertaining to these mAbs are shown in groups as in- 
dicated. The affinity of 2.9  x  10 -7 M -1 obtained (Table 3) is con- 
sistent with previous affinity measurements of the parent 36-71 
mAb (34,  39) and with the finding that mutations in the 
36-71 V~ do not contribute greatly to the high affinity of 
this mAb (39). 
The  K,'s  for  Ars-tyrosine  of unmutated canonical  V 
regions have been previously shown to range from 5  x  104 
to 2  x  106, depending on the combination of amino acids 
present at the VwD and D-JH junctions (39, 41). Most of 
the mAbs encoded by endogenous V segments have affinities 
at the high end of or exceeding this range,  and all of these 
antibodies have Ka's equal to or greater than the median of 
this range. Unexpectedly, all of the transgene-encoded anti- 
bodies have affinities equal to or higher than their unmu- 
tated counterparts, as represented by the FF29-34-1  mAb. 
Moreover, both endogenous and transgene VH-encoded an- 
tibodies expressed by hybridomas isolated from the same mice 
(grouped in Table 3) display this property of increased affinity 
relative to their unmutated precursors. 
Discussion 
At the outset of these experiments, we anticipated that 
expression of the unusually high affinity antibody encoded 
by the 36-71 VH transgene could influence the outcome of 
the anti-Ars response via both (a) trans effects on B cell clones 
expressing endogenous antibody genes mediated by direct or 
indirect interaction of these clones with transgene-expressing 
clones or by secreted transgene-encoded antibody; and (b) 
cis  effects  of the  transgenic  antibody  on  the  transgene- 
expressing clones themselves. The kinetics of serum antibody 
production, extent and type of isotype dass switching, and 
intrinsic degree of V gene somatic hypermutation were in- 
distinguishable in transgene- and endogenous V  gene-ex- 
pressing anti-Ars clones (Tables 1 and 2 and Figs. 3 and 4). 
Moreover, none of these parameters varied appreciably from 
those measured in nontransgenic A/J mice. This demonstrates 
a lack of either c/s or trans effects of transgene expression on 
the respective underlying processes, indicating that relative 
affinity of sIg for antigen does not play a role in the regula- 
tion of these processes. This regulation appears to act in a 
"global" fashion with respect to all responding B cell clones. 
Previous observations  support the notion that regulation of 
class switching occurs  in such a global fashion  (46,  47). 
The finding that somatic hypermutation takes place to the 
same extent, and apparently with similar timing in transgene- 
and endogenous VH-expressing clones, was unexpected. We 
reasoned that after the initiation of the GC reaction, clones 
expressing transgene-encoded canonical V regions might ei- 
ther rapidly exit GCs, since the affinity of their sIg relative 
to endogenous affinities would be extremely high, or be cap- 
able of increased iterations of the mutation-selection cycle 
relative to endogenous clones due to an enhanced intra-GC 
proliferative or survival potential afforded by their high affinity 
sIg. Given these scenarios, if the GC microenvironment is 
requisite for hypermutation, then transgeuic V regions would 
display either reduced or increased mutation frequency com- 
pared with their endogenous counterparts. Neither was the 
case, indicating that the affinity of a B cell clone's slg does 
not directly affect the hypermutation process in this clone. 
It has been suggested that hypermutation takes place pre- 
dominantly within the GC centroblast population, before 
antigen selection of centrocyte derivatives of this population 
(48). The spatial and temporal uncoupling of hypermutation 
and  selection  predicted by  this  model,  with  a  corollary 
predicting limited reentry of centrocytes into the centroblast 
pool, could explain  our observations. 
The model shown in Fig. 2 D best accounts for the be- 
havior in the anti-Ars response of clones initially expressing 
unmutated forms of the 36-71 VH gene and a canonical VK 
gene. The high affinity of these clones' slg appears to lead 
to predominant participation in the AFC response. This is 
probably due to a high relative efficiency of antigen capture, 
leading to focusing of CD4 T  cell help. Nevertheless,  this 
predominant participation does not significantly alter the AFC 
response mounted by endogenous clones. The high affinity 
of the sIg of transgene-expressing clones also ensures partici- 
pation in the GC/Bm pathway, but again does not greatly 
alter participation of endogenous  clones in this pathway. Thus, 
the degree of participation in both the AFC and GC/Bm 
pathways appears to be regulated only in c/s by the transgene. 
Our data do not rule out an effect of differences in precursor 
frequency between B cells expressing transgene-encoded and 
endogenous canonical V regions, although both frequencies 
are dearly low (see Materials and Methods). Experiments using 
several lines of mice containing a 36-65 V8 transgene that 
forms hybrid loci have shown that transgene-expressing clones 
give rise to lower frequencies of primary and secondary hy- 
bridomas than are observed in 36-71 VH-transgenic mice. 
This argues that predominant participation of 36-71 trans- 
gene-expressing clones in the anti-Ars response is largdy due 
to the very high affiuity for Ars endowed by expression of 
this transgene. 
The models shown in Fig. 2, A and B, can be ruled out, 
as major fractions of primary anti-Ars serum antibody have 
high affinity for Ars and are E4 +,  i.e.,  they appear  to be 
transgene encoded, and secondary transgene-expressing hy- 
bridomas display extensive somatic mutation of their VH and 
VK genes. The model shown in Fig. 2 C, exclusive and pre- 
cocious participation of transgene-expressing clones in the 
GC/Bm pathway, is also not supported by the serological 
analyses. Moreover, none of the transgene-expressing primary 
hybridomas were found to express mutated V genes, demon- 
strating that the somatic hypermutation process was not ac- 
celerated in transgene-expressing clones. Modified forms of 
this model proposing multiple stages of GC devdopment  could 
be considered, however. Indeed, it has been suggested that 
many B ceils exit the GC to form AFC before the initiation 
of hypermutation (49). 
Perhaps the most striking conclusion to be made from our 
analyses is that the affiuity requisite for formation of Bm ceils 
by a done is not determined by the "average" affinity of the 
antibodies produced by all responding clones.  Rather, this 
requisite  affinity seems to be defined by the affinity of the 
antibodies expressed by only this clone before the hypermu- 
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indicating cis effects of the transgene:  (a) all mAbs produced 
by transgene-expressing secondary hybridomas tested had 
K,'s larger than their "starting" affinities (2.9  x  107), while 
all mAbs produced by endogenous V region-expressing hy- 
bridomas tested had K,'s substantially lower than this value 
and in the range expected for antibodies expressed by sec- 
ondary hybridomas isolated from Ars-immunized conventional 
A/J mice (21) (Table 3); (b) secondary hybridomas expressing 
transgenic VH or endogenous canonical VH genes were iso- 
lated at similar frequencies. Moreover, many of the endoge- 
nous V region-expressing hybridomas were isolated from mice 
that also yielded transgene-expressing hybridomas. 
It is well documented that GCs are formed by only a small 
number of B cells (47, 50). The oligoclonality of newly formed 
GCs appears to be further reduced before the onset of hyper- 
mutation (47), perhaps due to an affinity "cutoff" imposed 
by the loss of slgD (12, 51, 52). The resulting pauciclonality 
of GCs during the mutation selection period would make 
it extremely unlikely that two clones specific for the same 
epitope were resident in the same GC. Physical isolation of 
multiple clones expressing slg specific for identical epitopes 
but of different affinities would allow "clone-autonomous" 
regulation of the postmutation affinity-based  Bm selection 
process. 
Current data, however, do not provide a satisfactory ex- 
planation for the mechanism of such a clone-autonomous se- 
lection process. If deposition of circulating Ag:Ab complexes 
on the surface of FDCs is a prerequisite for GC formation 
(53),  then the antibody present in these complexes should 
be of polyclonal origin. In the 36-71 VH-transgenic mice, 
"testing" of the affinity of slg expressed by GC B cells rela- 
tive to this polyclonal Ig should have resulted in a normaliza- 
tion of the slg affinity of transgene and endogenous VH-ex- 
pressing clones, i.e., endogenous affinities would increase and 
transgene affinities would decrease. The latter was not ob- 
served. One possible explanation is that upon entry into the 
GC, before hypermutation, B cell clones secrete antibody that 
binds, perhaps monovalently, to a limited number of avail- 
able epitope sites on FDC-bound Ag:Ab complexes. After 
hypermutation,  competition for  binding  to  this  limited 
number of sites between the secreted antibody and mutant 
antigen receptors could allow selection of slg mutants with 
increased affinity. Alternatively, we have previously proposed 
a model for affinity maturation based on sequential expres- 
sion and testing of different mutant forms of a V region by 
single B cells (54). Due to DNA replication of expressed V 
genes in the absence of cell division, during which the repli- 
cation of only one strand was assumed to be error prone, 
this model allowed for reversion to the expression of an un- 
mutated V gene by individual cells. Successive cycles of ex- 
pression of mutated and unmutated V regions by a single 
B cell might allow this cell to detect the acquisition of a mu- 
tant V region with increased  affinity relative to its unmu- 
tated precursor, based on increased relative signaling through 
the antigen receptor complex. Detailed analysis of the inter- 
action of B cells and FDCs during the GC reaction, and 
determination of whether affinity-based selection takes place 
exclusively as a consequence of this interaction, will be re- 
quired to gain insight into the mechanism of clone-auto- 
nomous affinity maturation and Bm generation. 
Regarding the mechanism of hypermutation, the finding 
that mutation took place to similar extents in transgenic and 
endogenous VH genes reinforces previous observations  that 
extensively mutated V genes remain good substrates for hyper- 
mutation (55).  It has been suggested that gene conversion 
between functional V genes and unrearranged V gene seg- 
ments of V pseudogenes over short stretches of DNA may 
play a role in the hypermutation process (56).  While it is 
now widely accepted that most of the mutations in mouse 
V genes and their flanking sequences arise de novo, the pos- 
sibility that a subset of somatic mutations are templated has 
received some support (57,  58). 
The B cell precursors  to the secondary hybridomas ex- 
pressing endogenous canonical  VH gene contained a large 
"reservoir" of potential donors for "microconversion" events 
in the form of the multicopy 36-71 Vn-transgenic array. In 
addition, hybrid loci are formed by interchromosomal "macro" 
gene conversion events between such transgenic arrays and 
the Igh locus (28). Furthermore, three of the codons present 
in the 36-71 VH encode amino acids that individually and 
additively confer increased affinity for Ars when introduced 
into an unmutated canonical V region (39), and so could be 
selected by antigen. Two of these codons arose in the 36-71 
V,  via  somatic mutation (58  ACT  to ATT,  59 AAG to 
ACG), and one is present at the D-JH junction (107 AAG). 
Fig. 4 shows that none of the 18 endogenous canonical VH 
sequences contains AAG at codon 107.  Several of these se- 
quences contain the ATT change at codon 58, and one con- 
tains the ACG change (ACC in this case) at codon 59. How- 
ever, both of these changes are recurrently observed among 
canonical V regions isolated from conventional A/J mice (43). 
Of particular significance, none of the sequences contain both 
of these changes, despite that fact that a "micro" gene con- 
version event involving only two adjacent codons could simul- 
taneously introduce them. Of the other base changes present 
in the 36-71 VH transgene, only one is found in the endog- 
enous VH sequences: a TAC to AAC change at codon 32. 
However, this change is also recurrently observed in the ca- 
nonical VH genes of conventional A/J mice (43),  and the 
codon present at position 32 in the 36-71 VH is an AAT. 
The third position C-to-T change is silent, yet none of the 
endogenous sequences that contain the first position T-to-A 
change also contain this silent change. In toto, these observa- 
tions suggest that micro gene conversion events between the 
36-71 VH transgenic array and expressed endogenous canon- 
ical VH genes did not take place. 
Finally, the differences in mutation frequencies and R/S 
ratios observed between the endogenous and transgene-en- 
coded VH  genes (Table 2)  suggest that  there are limited 
"mutational solutions" to acquiring increased affinity among 
canonical anti-Ars V regions, and the number of such solu- 
tions decreases  with increasing affinity. Indeed, smaller affinity 
increases relative to precursors were observed among transgene- 
279  Vora and Manser encoded secondary antibodies than among endogenous sec- 
ondary  antibodies  (Table  3),  implying  that  transgene-ex- 
pressing clones may have been approaching a "global affinity 
optimum" (59, 60). Nevertheless,  affinity maturation did take 
place within 36-71 VH transgene-expressing clones in a short 
period of time, providing further testimony to the exquisite 
stringency of the affinity-based selection process (8, 26, 61). 
Indeed, our data suggest that what limits affinity matura- 
tion in normal mice is not antigen selection, but the genera- 
tion of V  region mutants. This is surprising given the ex- 
ceedingly high rate at which hypermutation takes place (62). 
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